ALB and osteosarcoma: A modified MAP regimen consisting of MTX‐ or DOX‐adsorbed HSA‐TPP NCs and free cisplatin displays a higher synergistic anticancer effect in HOS/MNNG human osteosarcoma cells than conventional MAP.